Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of MET-3 in Obese Human Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03660748
Recruitment Status : Recruiting
First Posted : September 7, 2018
Last Update Posted : October 5, 2018
Sponsor:
Collaborator:
Glycemic Index Laboratories, Inc
Information provided by (Responsible Party):
NuBiyota

Brief Summary:
A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with MET-3 in obese subjects

Condition or disease Intervention/treatment Phase
Obesity Biological: MET-2 Early Phase 1

Detailed Description:
This is an open label, single center, uncontrolled pilot study of 20 participants; each group will receive a different dose of MET-3. Each group will have 4-6 females, 4-6 participants with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9 kg/m.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study design is open label, single center, uncontrolled pilot study of 20 participants divided into 2 groups of 10; each group will receive a different dose of MET-3. Each group will have 4-6 females, 4-6 participants with BMI 30.0-34.9 kg/m² and the remainder with BMI 35-39.9 kg/m.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of Microbial Ecosystem Therapeutics (MET)-3 in Obese Human Subjects
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : September 1, 2019

Arm Intervention/treatment
Experimental: Lower BMI
Use of MET-2 in subjects with BMI of 30.0 to 34.9
Biological: MET-2
Ingestion of a novel human microbiome preparation

Experimental: Higher BMI
Use of MET-2 in subjects with BMI of 35 to 39.9
Biological: MET-2
Ingestion of a novel human microbiome preparation




Primary Outcome Measures :
  1. Effect of MET-3 on the Incremental Area under the glucose curve (2 hrs) in obese subjects [ Time Frame: Treatment week 6 ]
    The area under the glucose curve in obese subjects will be measured 2 hours after a 75 g oral glucose challenge. This measurement will be made at baseline and then again after 6 weeks of treatment with MET-3.


Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events [ Time Frame: Period beginning at enrollment and continuing through to end of treatment phase (week 6) ]
    Adverse Events,Complete blood count (CBC), aspartate transaminase (AST), alanine aminotransferase (ALT), Alkaline phosphatase (ALP), bilirubin, urea, amylase, creatinine and electrolytes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   4 - 6 non-pregnant, non-lactating females in each group of 10 subjects
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or non-pregnant, non-lactating females who are taking adequate contraceptive precaution, aged 18 to 75 years inclusive;
  2. BMI ≥30.0 kg/m2 and <40.0 kg/m2;
  3. Stable body weight (±4 kg) for the past 4 months with no intention to gain or lose weight;
  4. Fasting serum triglycerides <6 mmol/L (<532 mg/dL) at screening;
  5. Fasting serum glucose <7.0 mmol/L (<126 mg/dl) and A1c<6.5% at screening
  6. Blood pressure <160/100.
  7. AST, ALT and ALP ≤1.8 times the upper limit of normal (liver function) at screening;
  8. Serum creatinine < 1.5 times the upper limit of normal (kidney function) at screening;
  9. At least one of the following:

    • Fasting serum glucose >5.6 mmol/L
    • HbA1c > 6.0%
    • Fasting triglycerides >1.70 mmol/L (150 mg/dl)
    • AST > upper limit of normal
    • Blood pressure, systolic >140 mmHg and/or diastolic >90 mmHg
  10. Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial;
  11. Willing to abstain from strenuous exercise, consuming alcoholic drinks 24 hours before study days and during study days;
  12. Willing to maintain current dietary supplement and medication use throughout the trial. On test days, subject agrees to bring any dietary supplements or medications taken in the morning with them to GI labs to take just prior to the glucose test meal;
  13. Subject is not currently participating nor recently (within 30 days of screening) participated in a clinical trial involving long-term exposure (greater than 24 hours) to an investigational drug, nutritional supplement or lifestyle modification;
  14. Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator and other authorized agents as indicated in the consent form

Exclusion Criteria:

  1. Failure to meet any one of the inclusion criteria.
  2. Smokers
  3. Hemoglobin measurements of <120g/L for females and <130g/L for males (as per World Health Organization [WHO] criteria for anemia)
  4. Known history of acquired immune deficiency syndrome (AIDS), hepatitis, a history or presence of clinically important endocrine conditions (including Type 1 or Type 2 diabetes mellitus), pulmonary, biliary or gastrointestinal (GI) disorders or new onset cardiovascular disease within 6 months of screening (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke).
  5. Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might, in the opinion of the Investigator, either: 1) make participation dangerous to the subject or to others, 2) affect the results, or 3) influence the ability of the subject to comply with study procedures.
  6. Major trauma or surgical event within 3 months of screening.
  7. Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines.
  8. Known intolerance, sensitivity or allergy to any ingredients in the investigational agent.
  9. Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
  10. Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.
  11. Presence of any signs or symptoms of an active infection within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment (i.e. antibiotic therapy) has been completed at least 5 d prior to each test visit.
  12. History of cancer in the prior two years, except for non-melanoma skin cancer.
  13. Recent history (within 12 months of screening) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as > 14 drinks per week (1 drink=12 oz beer, 5 oz wine, or 1.5 oz distilled spirits).
  14. Pregnancy or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03660748


Contacts
Layout table for location contacts
Contact: Thomas MS Wolever, MD/PhD 416.861.0506 ext 210 twolever@gilabs.com
Contact: Alexandra Jenkins, PhD 416.861.0506 ext 200 alexandrajenkins@gilabs.com

Locations
Layout table for location information
Canada, Ontario
GI Labs Recruiting
Toronto, Ontario, Canada, M5C2N8
Contact: Adish Ezatagha, MSc    416 861-9782 ext 208    aezatagha@gilabs.com   
Contact: Alexandra L Jenkins, PhD / RN    416 861-9782 ext 200    alexandrajenkins@gilabs.com   
Sponsors and Collaborators
NuBiyota
Glycemic Index Laboratories, Inc
Investigators
Layout table for investigator information
Principal Investigator: Thomas MS Wolever, MD/PhD GI Labs

Layout table for additonal information
Responsible Party: NuBiyota
ClinicalTrials.gov Identifier: NCT03660748     History of Changes
Other Study ID Numbers: MET-3 101
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: October 5, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by NuBiyota:
human microbiota